Achillion investors got a huge piece of bad news on Monday evening, when this biotech virology specialist announced that its lead protease inhibitor for hepatitis C , sovaprevir, has been placed on clinical hold by the FDA after troubling safety data.
http://seekingalpha.com/article/1531232-how-bad-will-the-partial-hold-on-sovaprevir-be-for-achillion?source=feed
http://seekingalpha.com/article/1531232-how-bad-will-the-partial-hold-on-sovaprevir-be-for-achillion?source=feed
No comments:
Post a Comment